A BLOODY DEMANDING BIOPSY: A CASE OF A 54 YO M WITH STEMI FOLLOWING TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY
Introduction/Objective: Transrectal ultrasound guided prostate biopsy (TRUSGPB) is a common procedure with minor risks. Presented is a case highlighting a complication and reinforcing current USPSTF guidelines. 54 year old African American male with PMH of hyperlipidemia presented to clinic requesting screening PSA, which was elevated and he underwent TRUSGPB. He then developed hematochezia with chest pain that was radiating into his arm. EKG demonstrated ST elevation and cardiac enzymes were abnormal. He underwent a PCI where complete occlusion of the LAD was noted. His BRBPR continued and he developed hematuria leading to hemodynamic instability, ultimately requiring a transfusion. Flexible sigmoidoscopy revealed middle rectal artery bleeding that required intervention. Prostate biopsy showed adenocarcinoma (Gleason 6). Methods: Chart review and PubMed search of relevant keywords were performed. Discussion/Conclusion: Prostate cancer screening is no longer recommended by USPSTF given risks of diagnosis and treatment outweigh benefits. TRUSGPB is the diagnostic tool of choice. Complications are often minimal and self-limited, but severe complications such as hemorrhage can occur. Gleason score of 6, is a common form of prostate cancer where surveillance can initially be chosen, but the majority will eventually be treated. This case supports the USPSTF recommendation against routine prostate cancer screening. Although cancer was confirmed, it is unclear if early identification outweighs possible complications. The complications suffered by this patient gives further evidence of the risks associated with PSA screening without a clear benefit. It also emphasizes the potential need for cardiovascular screening prior to minor procedures to reduce morbidity and mortality.